Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention?
Fournier
Albert
A
Choukroun
Gabriel
G
Modeliar
Santhi Samy
SS
Godefroy
Olivier
O
Achard
Jean-Michel
JM
Wang
Jiguang
J
Messerli
Franz
F
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D017209:Apoptosis; D001794:Blood Pressure; D002118:Calcium / Q000037:antagonists & inhibitors*; D002318:Cardiovascular Diseases / Q000473:pathology; D004095:Dihydropyridines / Q000627:therapeutic use*; D006801:Humans; D015995:Prevalence; D012008:Recurrence; D012306:Risk; D020521:Stroke / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D004095:Dihydropyridines; C038806:1,4-dihydropyridine; D002118:Calcium